PM
NKTR icon

Parametrica Management’s Nektar Therapeutics NKTR Stock Holding History

Parametrica Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-911
Closed -$226K – 193
2020
Q3 		$226K Buy
+911
New +$287K 0.43% 70
2018
Q1 		– Sell
-519
Closed -$465K – 353
2017
Q4 		$465K Buy
+519
New +$307K 0.29% 76

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Parametrica Management's NKTR Position: Q4 2020 in Review

Parametrica Management sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 911 shares — an estimated $226K sold.

Parametrica Management first reported a position in NKTR in Q4 2017 and held it in 2 quarters. The position peaked at $465K in Q4 2017. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Parametrica Management reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parametrica Management sold 911 Nektar Therapeutics shares in Q4 2020, an estimated $226K.
  • Parametrica Management first reported a position in Nektar Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parametrica Management's Nektar Therapeutics position peaked at $465K in Q4 2017.
  • 246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Parametrica Management's 13F filing for Q4 2020, filed 16 Feb 2021.